Clinical trials: Adjuvant Drug Therapy
Nasopharyngeal Neoplasms
ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
This study will enroll patients with non-metastatic nasopharyngeal carcinoma (NPC) that have residual Epstein-Barr virus (EBV) DNA after curative radiotherapy or chemoradiotherapy.
- Trial name
- ADVANCE (NCT02874651)
- Testing
- Apatinib
- Where
- 3 sites in China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Uterine Cervical Cancer
Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer
The scope of the trial is to assess the efficacy of the association gemcitabine-cisplatin + radiotherapy followed by an adjuvant chemotherapy
- Trial name
- GEMCOL (NCT00421096)
- Testing
- Gemcitabine, Radiotherapy, Cisplatin
- Where
- 2 sites in France
- Volunteers
- 19 people
- Sponsor
- Centre Oscar Lambret
Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after…
- Trial name
- STELLAR (NCT02796261)
- Testing
- Eflornithine, Lomustine
- Where
- 79 sites in United States, Belgium and 6 more
- Volunteers
- 343 people
- Sponsor
- Orbus Therapeutics, Inc.
Breast Cancer
Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- 12-93 (NCT00002529)
- Testing
- cyclophosphamide, doxorubicin hydrochloride, epirubicin hydrochloride
- Where
- 20 sites in Australia, Italy and 5 more
- Volunteers
- 452 people
- Sponsor
- ETOP IBCSG Partners Foundation
Resected Pancreatic Adenocarcinoma
Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX
Induction mFOLFIRINOX has become the standard in the management of locally advanced and borderline adenocarcinoma. Following the results of the PREOPANC-01 JASP-05, NEONAX studies it is expected that the neoadjuvant approach will…
- Trial name
- PANACHE 02 (NCT07044453)
- Testing
- Gem/Nabpaclitaxel infusion, mFOLFIRINOX infusion
- Where
- France
- Volunteers
- 390 people
- Sponsor
- University Hospital, Rouen
HIV Infections
Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
The purpose of this study is to see if giving HIV-positive patients an HIV vaccine plus anti-HIV drugs can help lower HIV levels in the blood (viral load).
- Trial name
- NCT00005001
- Testing
- HIV-1 Immunogen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Agouron Pharmaceuticals
Breast Cancer
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC
Circulating tumor DNA (ctDNA) has been demonstrated to be an effective prognostic marker in breast cancer. Various studies have shown that early TNBC breast cancer patients with positive ctDNA have high risk of cancer recurrence…
- Trial name
- Artemis (NCT04803539)
- Testing
- capecitabine, capecitabine + camrelizumab + apatinib
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non Small Cell Lung Cancer, EGFR Gene Mutation
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
This is an open-label, non-randomised, phase II, multi-centre clinical trial 26 patients will be enrolled in this trial to evaluate the major pathologic response in patients with neoadjuvant treatment with Carboplatin Pemetrexed…
- Trial name
- NCT04512430
- Testing
- Atezolizumab, Bevacizumab, Carboplatin
- Where
- 18 sites in Spain
- Volunteers
- 4 people
- Sponsor
- Fundación GECP
Biliary Tract Cancer
Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
The aim of this study is to assess the efficacy and safety of durvalumab combined with S-1 as adjuvant therapy of resectable Biliary Tract Cancer(BTC) with high risk of recurrence
- Trial name
- NCT06490107
- Testing
- Durvalumab combined with S-1
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer
A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)
This is a controlled study designed to compare relapse-free survival and overall survival in patients receiving UFT with those in patients receiving surgery alone.
- Trial name
- NCT00152230
- Testing
- UFT (uracil, tegafur), Surgery alone
- Where
- Japan
- Volunteers
- 900 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
This is an randomized, controlled, multicenter phase 3 clinical trial. The purpose of this study is to evaluate the efficacy and safety of single-agent capecitabine as adjuvant chemotherapy in locoregionally advanced…
- Trial name
- CAN (NCT02958111)
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 406 people
- Sponsor
- Sun Yat-sen University
Lymphoma
PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy
The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.
- Trial name
- NCT03647072
- Testing
- CHOP, CHOP Plus Lanzoprazole, CHOP Plus Famotidine
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sherief Abd-Elsalam
Colorectal Cancer Metastatic
Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases
Chemotharapy plus targeted therapy regimen, as an adjuvant therapy, can effectively reduce the rate of both intrahepatic and extrahepatic recurrence in initially unresectable CRLM patients.
- Trial name
- NCT06027775
- Testing
- Targeted agent
- Volunteers
- 198 people
- Sponsor
- Fudan University
Glioblastoma, Malignant Glioma
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
This study is for newly diagnosed WHO Grade IV malignant glioma patients to determine whether an investigational drug known as marizomib (MRZ) will improve the treatment of newly diagnosed glioblastoma patients by delaying the…
- Trial name
- NCT02903069
- Testing
- MRZ, TMZ, RT
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 66 people
- Sponsor
- Celgene
Colon Cancer
Early Commencement of Adjuvant Chemotherapy for Colon Cancer
This study sets up the final study end point and three detailed goals as the following. The main objective of study: This trial is done to assess the safety and benefit of early adjuvant chemotherapy from 10 to 14 days after…
- Trial name
- ECTX (NCT01460589)
- Testing
- timing to initiate the adjuvant FOLFOX chemotherapy
- Where
- 2 sites in South Korea
- Volunteers
- 303 people
- Sponsor
- Kyungpook National University Hospital
Gastric, Esophagogastric Junction
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
This study aims to assess the efficacy and safety of neoadjuvant adjuvant treatment with durvalumab in combination with FLOT compared to placebo in combination with FLOT in Chinese patients with Resectable Gastric and…
- Trial name
- NCT07877818
- Testing
- FLOT Chemotherapy, Durvalumab
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Osteosarcoma of Pelvis
Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum
To study the effect of the timing of surgery on outcome of patients with nonmetastatic osteosarcoma of pelvis and sacrum.
- Trial name
- NCT03360760
- Testing
- Doxorubicin, Cisplatin, Methotrexate
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Triple Negative Breast Cancer
Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC
The prescription of neoadjuvant chemotherapy becomes a standard in women with HER2-positive or triple-negative breast cancer and allows a complete histological response (pCR) which represents a prognostic factor for survival. .
- Trial name
- MIMOSA (NCT04368468)
- Testing
- biomarker evolution
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut Claudius Regaud
Cervical Cancer
Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility
If no metastases are observed, patients will start a short protocol of four courses of weekly neo-adjuvant chemotherapy (12 weeks).
- Trial name
- NEOCON-F (NCT03852979)
- Testing
- Paclitaxel, Carboplatin, conisation
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- The Netherlands Cancer Institute
Non-Small Cell Lung Cancer
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in…
- Trial name
- NCT02486718
- Testing
- Atezolizumab, Cisplatin, Vinorelbine
- Where
- 216 sites in United States, Australia and 20 more
- Volunteers
- 1,280 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.